All Stories

  1. American Society of Metabolic and Bariatric Surgery review of gut microbiome and alterations related to weight loss treatment, by the Clinical Issus Committee
  2. Diabetes status and not preoperative glycemic control is associated with postoperative outcomes in metabolic/bariatric surgery
  3. Association of Obesity Severity With Cardiometabolic and Renal Disease Burden in the United States
  4. Roux-en-Y Gastric Bypass is Associated With Increased Intestinal Glucose Uptake in Humans
  5. Association of socioeconomic disparities by payor status and perioperative outcomes in bariatric surgery
  6. Impact of heart failure on postoperative outcomes in bariatric surgery
  7. Impact of preoperative liver disease diagnosis on postoperative outcomes in bariatric surgery
  8. Association of insurance status with postoperative resource utilization after metabolic/bariatric surgery—A multi-institutional study
  9. Longitudinal changes in positive airway pressure device use after metabolic surgery: a 3-year matched cohort study of National Claims Data
  10. Bile diversion underlies Roux-en-Y antitumor benefits
  11. Multi-modal neo-adjuvant anti-obesity medications may be more effective than medically supervised weight loss or GLP-1 therapy alone in preparing BMI≥70 patients for metabolic surgery
  12. Comment on: Variation in opioid-free discharge after metabolic surgery from 2018 to 2023: a state-wide analysis from the Michigan Bariatric Surgery Collaborative
  13. Patient and operative characteristics of readmission and poly-readmission following metabolic surgery: an MBSAQIP analysis (2015–2021)
  14. American Society for Metabolic and Bariatric Surgery Review of Body Composition
  15. Comment on: Perioperative lifestyle and nutritional interventions' details reporting in bariatric surgery trials according to the TIDieR checklist: a cross-sectional study
  16. Total Alimentary Limb Length Is Not Associated with Weight Loss Following Proximal Roux-en-Y Gastric Bypass
  17. Reduced Risk of Cardiovascular Diseases After Bariatric Surgery Based on the New Predicting Risk of Cardiovascular Disease EVENTs Equations
  18. American Society for Metabolic and Bariatric Surgery review of the body mass index
  19. Identifying At-Risk Populations for Reoperations, Readmissions, and Interventions in MBSAQIP Using a Novel Inpatient Postoperative Care Metric
  20. Patient Preferences for Metabolic Surgery: Do Patient Demographics Make a Difference?
  21. FGF21 acts in the brain to drive macronutrient-specific changes in behavioral motivation and brain reward signaling
  22. Changes in insulin sensitivity and gut peptides 8 and 52 weeks after bariatric surgery or low‐calorie diet
  23. Association Between Patient Portal Engagement and Weight Loss Outcomes in Patients After Bariatric Surgery: Longitudinal Observational Study Using Electronic Health Records
  24. Rare events model of the MBSAQIP database: risk of early bowel obstruction following metabolic surgery
  25. High prevalence of dysfunctional uterine bleeding in candidates for metabolic/bariatric surgery: increased endometrial cancer risk?
  26. Using a modified SAMANTA score to screen at-risk women seeking bariatric surgery for postmenopausal or abnormal uterine bleeding
  27. Early marginal ulceration prevalence following primary RYGB: a rare events model of the MBSAQIP 2015-2021
  28. Insurance payor status and risk of major adverse cardiovascular and cerebrovascular events after metabolic and bariatric surgery
  29. Comment on: Evaluating the incidence, risk factors, and postoperative complications associated with leaks following duodenal switch procedures: an analysis of the MBSAQIP
  30. Impact of progressive chronic kidney disease stage on postoperative outcomes in metabolic surgery—a propensity-matched analysis using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement database
  31. Limitations of the 2015–2021 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program database for emergency bariatric operations
  32. Bioenergetic Atlas of Small Intestinal Mucosal Mitochondria
  33. Clinical Outcomes of Metabolic Surgery on Diuretic Use in Patients With Heart Failure
  34. FGF21 as a mediator of adaptive changes in food intake and macronutrient preference in response to protein restriction
  35. Reduced Risk of Cardiovascular Diseases after Bariatric Surgery Based on the New PREVENT Equations
  36. BMI ≥ 70: A Multi-Center Institutional Experience of the Safety and Efficacy of Metabolic and Bariatric Surgery Intervention
  37. Sex- and operation-dependent effects on 5-year weight loss results of bariatric surgery
  38. Metabolic surgery: The sooner the better for long‐term success?
  39. Cardiometabolic Improvements After Metabolic Surgery and Related Presurgery Factors
  40. FGF21 acts in the brain to drive macronutrient-specific changes in behavioral motivation and brain reward signaling
  41. Invited Commentary: Preconception maternal gastric bypass surgery and the impact on fetal growth parameters
  42. Enhanced Patient Portal Engagement Associated with Improved Weight Loss Outcomes in Post-Bariatric Surgery Patients
  43. Comment on: Glycemic variability and hypoglycemia before and after Roux-en-Y gastric bypass and sleeve gastrectomy—a cohort study of females without diabetes
  44. Comment on: Short-term cardiovascular events after bariatric surgery in patients with metabolic syndrome
  45. Endoscopic sleeve gastroplasty and its role in the treatment of obesity: a systematic review
  46. Weight‐independent effects of Roux‐en‐Y gastric bypass surgery on remission of nonalcoholic fatty liver disease in mice
  47. Bariatric surgery alters mitochondrial function in gut mucosa
  48. Comment on: Resting-state network functional connectivity before and after bariatric surgery
  49. The Vagus Nerve Mediates Gut-Brain Response to Duodenal Nutrient Administration
  50. Physiology Reconfigured: How Does Bariatric Surgery Lead to Diabetes Remission?
  51. Regulation of body weight: Lessons learned from bariatric surgery
  52. Effect of high-risk factors on postoperative major adverse cardiovascular and cerebrovascular events trends following bariatric surgery in the United States from 2012 to 2019
  53. Combination anti‐obesity medications to effectively treat bariatric surgery weight regain at an academic obesity center
  54. The role of bariatric and metabolic surgery in the development, diagnosis, and treatment of endometrial cancer
  55. Feasibility of robotic repair of parastomal hernias
  56. 237-LB: Weight-Independent Effects of Roux-en-Y Gastric Bypass Surgery on Remission of Nonalcoholic Fatty Liver Disease in Mice
  57. Comment on: Measures of glucose homeostasis during and after duodenal exclusion using a duodenal-jejunal bypass liner in a normoglycemic, nonobese canine model
  58. Diabetes control before metabolic and bariatric surgery
  59. Comment on: The effect of sleeve ablation of gastric mucosa on body weight and glucose homeostasis in the rat
  60. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis
  61. Protein Appetite at the Interface between Nutrient Sensing and Physiological Homeostasis
  62. Comment on: Outcomes of bariatric surgery in extreme obesity: results from the United Kingdom National Bariatric Surgery Registry for patients with body mass index over 70 kg/m2
  63. Is there a common etiology for dumping syndrome and postbariatric hypoglycemia?
  64. Comment on: The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class II/III obesity
  65. Clinical significance of diabetes control before metabolic surgery
  66. Gut-brain communication and obesity: understanding functions of the vagus nerve
  67. Cardiovascular Risk Reduction Following Metabolic and Bariatric Surgery
  68. Intestinal Lymph Collection via Cannulation of the Mesenteric Lymphatic Duct in Mice
  69. Prevalence of thiamine deficiency is significant in patients undergoing primary bariatric surgery
  70. Comment on: Fecal metagenomics and metabolomics reveal gut microbial changes after bariatric surgery
  71. Comment on: Knowledge, attitudes and behaviors of women during pregnancy after bariatric surgery
  72. Comment on: Prevalence of obstructive sleep apnea in an Asian bariatric population. An undiagnosed dilemma
  73. Roux-en-Y gastric bypass surgery improves hepatic glucose metabolism and reduces plasma kisspeptin levels in morbidly obese patients with type 2 diabetes
  74. The incidence of orthostatic intolerance after bariatric surgery
  75. Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery
  76. Metabolic Effects of Bile Acids: Potential Role in Bariatric Surgery
  77. Comment on: greater curvature as a gastric pouch for sleeve gastrectomy: a novel bariatric procedure. Feasibility study in a canine model
  78. Bile diversion, a bariatric surgery, and bile acid signaling reduce central cocaine reward
  79. Does Bariatric Surgery Affect Breast-Milk Composition?
  80. Surgical treatment of obesity
  81. Proline Precursors and Collagen Synthesis: Biochemical Challenges of Nutrient Supplementation and Wound Healing
  82. What is the impact on the healthcare system if access to bariatric surgery is delayed?
  83. Metabolic responses to exogenous ghrelin in obesity and early after R oux‐en‐ Y gastric bypass in humans
  84. Bile acids and bariatric surgery
  85. Arginine-Dual roles as an onconutrient and immunonutrient
  86. Jejunal administration of glucose enhances acyl ghrelin suppression in obese humans
  87. Recent Advances in Metabolic Surgery
  88. Early Surges in Fasting Plasma Bile Acids after Roux-en-y Gastric Bypass are due to Insulin-Sensitizing, Bacterially-Derived Secondary Bile Acids
  89. Early Increases in Bile Acids Post Roux-en-Y Gastric Bypass Are Driven by Insulin-Sensitizing, Secondary Bile Acids
  90. Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery
  91. Glycemic control in critically ill surgical patients: risks and benefits
  92. Pleural effusion following blunt splenic injury in the pediatric trauma population
  93. A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy Volunteers
  94. Ileal interposition improves glucose tolerance and insulin sensitivity in the obese Zucker rat
  95. Atypical Antipsychotics Rapidly and Inappropriately Switch Peripheral Fuel Utilization to Lipids, Impairing Metabolic Flexibility in Rodents
  96. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis
  97. Ileal interposition (IT) improves insulin sensitivity in the obese Zucker rat (ZR)
  98. Hormonal and Metabolic Effects of Olanzapine and Clozapine Related to Body Weight in Rodents*